Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection (vol 83, pg 757, 2009)

被引：1
|
作者：
Sather, D. Noah [1 ]
Armann, Jakob
Ching, Lance K.
Mavrantoni, Angeliki
Sellhorn, George
Caldwell, Zachary
Yu, Xuesong
Wood, Blake
Self, Steve
Kalams, Spyros
Stamatatos, Leonidas
机构：
[1] Seattle Biomed Res Inst, Seattle, WA 98109 USA
来源：
JOURNAL OF VIROLOGY | 2009年 / 83卷 / 09期
关键词：
D O I：
10.1128/JVI.00283-09
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
引用
收藏
页码：4713 / 4715
页数：3
相关论文
共 50 条
  • [41] Cure of Chronic Viral Infection and Virus-Induced Type 1 Diabetes by Neutralizing Antibodies (Retraction of vol 13, pg 67, 2006)
    Ejrnaes, M.
    von Herrath, M. G.
    Christen, U.
    JOURNAL OF IMMUNOLOGY RESEARCH, 2016, 2016
  • [42] Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1 (vol 80, pg 5211, 2006)
    Li, Bing
    Decker, Julie M.
    Johnson, Roy W.
    Bibollet-Ruche, Frederic
    Wei, Xiping
    Mulenga, Joseph
    Allen, Susan
    Hunter, Eric
    Hahn, Beatrice H.
    Shaw, George M.
    Blackwell, Jerry L.
    Derdeyn, Cynthia A.
    JOURNAL OF VIROLOGY, 2007, 81 (22) : 12716 - 12716
  • [43] Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments
    Hone, DM
    DeVico, A
    Fouts, TR
    Onyabe, DY
    Agwale, SM
    Wambebe, CO
    Blattner, WA
    Gallo, RC
    Lewis, GK
    JOURNAL OF HUMAN VIROLOGY, 2002, 5 (01) : 17 - 23
  • [44] Circulating (1→3)-β-D-glucan Is Associated With Immune Activation During Human Immunodeficiency Virus Infection (vol 70, pg 232, 2020)
    Mehraj, V
    Ramendra, R.
    Isnard, S.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (06) : 1265 - 1265
  • [45] The C3-V4 region is a major target of autologous neutralizing antibodies in human immunodeficiency virus type 1 subtype C infection
    Moore, Penny L.
    Gray, Elin S.
    Choge, Isaac A.
    Ranchobe, Nthabeleng
    Mlisana, Koleka
    Karim, Salim S. Abdool
    Williamson, Carolyn
    Morris, Lynn
    JOURNAL OF VIROLOGY, 2008, 82 (04) : 1860 - 1869
  • [46] INFECTION ENHANCEMENT OF DENGUE TYPE-2 VIRUS IN THE U-937 HUMAN MONOCYTE CELL-LINE BY ANTIBODIES TO FLAVIVIRUS CROSS-REACTIVE DETERMINANTS
    BRANDT, WE
    MCCOWN, JM
    GENTRY, MK
    RUSSELL, PK
    INFECTION AND IMMUNITY, 1982, 36 (03) : 1036 - 1041
  • [47] COMBINATION THERAPY FOR INFECTION DUE TO HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 (VOL 18, PG 516, 1994)
    CALIENDO, AM
    HIRSCH, MS
    CLINICAL INFECTIOUS DISEASES, 1994, 19 (02) : 379 - 379
  • [48] A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response
    Zhang, PF
    Bouma, P
    Park, EJ
    Margolick, JB
    Robinson, JE
    Zolla-Pazner, S
    Flora, MN
    Quinnan, GV
    JOURNAL OF VIROLOGY, 2002, 76 (02) : 644 - 655
  • [49] Human Immunodeficiency Virus Type-1 (HIV-1) Continues to Evolve in Presence of Broadly Neutralizing Antibodies More than Ten Years after Infection
    Chaillon, Antoine
    Braibant, Martine
    Hue, Stephane
    Bencharif, Samia
    Enard, David
    Moreau, Alain
    Samri, Assia
    Agut, Henri
    Barin, Francis
    PLOS ONE, 2012, 7 (08):
  • [50] INCREASED MORTALITY ASSOCIATED WITH VITAMIN-A-DEFICIENCY DURING HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 INFECTION
    SEMBA, RD
    GRAHAM, NMH
    CAIAFFA, WT
    MARGOLICK, JB
    CLEMENT, L
    VLAHOV, D
    ARCHIVES OF INTERNAL MEDICINE, 1993, 153 (18) : 2149 - 2154
12345